Tengion, a clinical-stage biotechnology company, has appointed A Brian Davis as chief financial officer (CFO). Davis joins after 15 years with Neose Technologies, a biopharmaceutical company using enzymatic technologies to develop improved protein therapeutics.
Davis advanced from controller to senior vice president (SVP) and CFO at Neose, and brings highly relevant experience to Tengion including raising over US$300m in public and private equity and debt, financial evaluation of business development transactions, treasury and cash management, SEC reporting, Sarbanes-Oxley compliance, and investor relations. Davis holds a BS in Accounting from Trenton State College and an MBA from the Wharton School of the University of Pennsylvania. He is a certified public accountant (CPA).
Linda Hearne, Tengion’s vice president, finance, will be stepping down from her role in order to relocate with her family overseas.
A report by broking group Marsh examines the repercussions from the administration of the South Korean company, which filed for bankruptcy protection at the end of August.
Global research by C2FO suggests that smaller businesses are less concerned with the repercussions of Brexit and the upcoming US presidential election.
A squeeze on skilled talent means it now takes an average of seven weeks to fill open permanent roles in finance in the UK according to new research from financial services recruitment firm Robert Half.
Early-stage merger and acquisition deals in Asia-Pacific show nearly 10% year-on-year growth in recent months.